The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study

• Published in: International urology and nephrology 2019-01, Vol.51 (1), p.27-32
• Main Authors: Cakir, Suleyman Sami, Degirmentepe, Recep Burak, Atalay, Hasan Anil, Canat, Halil Lutfi, Ozbir, Sait, Culha, Mehmet Gokhan, Polat, Emre Can, Otunctemur, Alper
• Format: Article
• Language: English
• Subjects: Adult; Anticholinergics; Bladder; Cholinergic Antagonists - administration & dosage; Cholinergic Antagonists - classification; Depression - diagnosis; Depression - physiopathology; Depression - therapy; Female; Health risk assessment; Humans; Medicine; Medicine & Public Health; Mental depression; Middle Aged; Nephrology; Observational studies; Patients; Sexual Dysfunction, Physiological - drug therapy; Sexual Dysfunction, Physiological - etiology; Sexual Dysfunction, Physiological - psychology; Statistical analysis; Treatment Outcome; Turkey; Urinary Bladder, Overactive - complications; Urinary Bladder, Overactive - drug therapy; Urology; Urology - Original Paper
• ISSN: 0301-1623; 1573-2584
• DOI: 10.1007/s11255-018-2030-7

Purpose The aim of the study was to determine the effect of anticholinergics used for overactive bladder treatment on the sexual function of women. Methods Between January 2016 and August 2018, over 18 years old, 216 sexual active women with OAB and 165 healthy women as control group were prospectively enrolled in the study. Five different anticholinergics were used for the treatment. Female Sexual Function Index (FSFI), eight-item overactive bladder awareness tool (OAB-V8), and Beck Depression Inventory form were completed before and after 3 months. Baseline and post-treatment scores were compared with a control group of age-matched healthy women. Results Patients with OAB reported at baseline significantly worse sexual function in all FSFI domains compared to healthy control group (21.47 ± 3.22 vs. 26.79 ± 5.56, p